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Chapter 7
The chemokine system in arteriogenesis and hind
limb ischemia
Paula K. Shireman, MD, San Antonio, Tex
Chemokines (chemotactic cytokines) are important in the recruitment of leukocytes to injured tissues and, as such, play
a pivotal role in arteriogenesis and the tissue response to ischemia. Hind limb ischemia represents a complex model with
arteriogenesis (collateral artery formation) occurring in tissues with normal perfusion while areas exhibiting ischemic
necrosis undergo angiogenesis and skeletal muscle regeneration; monocytes andmacrophages play an important role in all
three of these processes. In addition to leukocyte trafficking, chemokines are produced by and chemokine receptors are
present on diverse cell types, including myoblasts, endothelial, and smooth muscle cells. Thus, the chemokine systemmay
have direct effects as well as inflammatory-mediated effects on arteriogenesis, angiogenesis, and skeletal muscle
regeneration. This article reviews the complexity of the hind limb ischemia model and the role of the chemokine system
in arteriogenesis and the tissue response to ischemia. Special emphasis will be placed on the roles of monocytes/
macrophages and CCL2/monocyte chemotactic protein-1 (MCP-1) in these processes. ( J Vasc Surg 2007;45:48A-56A.)Arteriogenesis (collateral artery formation)1 and tissue
regeneration2 have great therapeutic promise for the treat-
ment of a wide variety of medical conditions. For example,
extremity injuries compromise 50% to 60% of all combat
casualties observed in Iraqi war veterans, resulting in blood
vessel injury, large soft tissue defects, and high amputation
rates.3,4 Skeletal muscle is the tissue most vulnerable to
ischemic damage in the extremities,5 but it also has an
amazing potential to regenerate.6 Myogenic progenitor
cells reside in skeletal muscle, proliferate, and fuse together
or with damaged muscle fibers to regenerate muscle.
Angiogenesis and inflammation are critical to the pro-
cess of muscle regeneration, but the complex interactions
between these multiple cells types are poorly understood.
In addition to inflammatory cell recruitment, chemokines
may also contribute to these complex processes by directly
acting on cell types other than inflammatory cells.1 A better
understanding of the mechanisms of arteriogenesis, skeletal
muscle regeneration, angiogenesis, and how inflammatory
cells and chemokines influence these processes could lead
to new therapies for limb salvage from ischemic and trau-
matic injury.
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48ACOMPLEXITY OF THE HIND LIMB ISCHEMIA
MODEL
Many studies have used animal hind limb ischemia
models to delineate the multiple factors that influence
arteriogenesis and the tissue response to ischemia. Numer-
ous mouse models have been used, ranging from simple
femoral artery ligation to extensive excisions of the femoral
artery, vein, and nerve,7 but multiple technical differences
can make comparisons difficult. Nevertheless, the complex
tissue responses to ischemia in the hind limb are different in
anatomically distinct regions. In areas of severe ischemic
injury, typically below the knee, muscle necrosis is accom-
panied by an intense inflammatory process, angiogenesis,
and muscle regeneration.8-10 In contrast, arteriogenesis
predominates in areas proximal to the ischemic regions (ie,
the thigh).8,10 Given these diverse pathophysiologic
events, it is important to consider each region separately.
In most hind limb ischemia models, the thigh is the
main site of arteriogenesis. Arteriogenesis is probably in-
duced by fluid shear stress within the developing collateral
arteries and is not initiated by hypoxia.11 Generally, necro-
sis is not present in the thigh muscles, and ischemia is mild
or absent.12,13 In the absence of hypoxia, capillary density
in the thigh does not increase after femoral artery liga-
tion.10
In contrast, an inflammatory infiltrate, angiogenesis,
and skeletal muscle regeneration occur when tissue necrosis
is present.8-10 Angiogenesis is induced by hypoxia, and
capillary density increases in areas of severe, acute isch-
emia.10,14 Tissue necrosis generally occurs in the muscles
below the knee, and the extent of necrosis varies in different
muscle groups. The tibialis anterior and soleus muscles
undergo extensive necrosis with regeneration, whereas the
gastrocnemius muscles exhibit variable necrosis after fem-
oral artery excision.8
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tion, and severity of necrosis.7,10,12 However, depending
on the extent of arterial disruption and mouse strain used,
necrosis can also occur in the thigh8,15 and if not directly
stated by the authors, can be inferred by the presence of a
robust inflammatory infiltrate in the early stages of ischemia
and the presence of centrally located nuclei (ie, regenerated
muscle fibers)16 after necrosis resolves. Of interest is that
chronic ischemia in rats in the below knee muscles, either
by placement of ameroid constrictors14 or ligation of the
iliac artery,17,18 results in increased capillary density in the
absence of tissue necrosis or inflammation. Given the diver-
sity of hind limb ischemia models, specification of the
muscle used, presence of necrosis, extent of arterial disrup-
tion and animal strain can assist in resolving seemingly
contradictory results.
BRIEF OVERVIEW OF CHEMOKINES AND
CHEMOKINE RECEPTORS
Chemokines (chemotactic cytokines) are important in
Table I. The CC family of chemokines and chemokine re
Receptor Chemokine ligands
CCR1 CCL3 (MIP-1), CCL5 (RANTES), CCL7
(MCP-3), CCL14 (HCC1)
T cell
bas
CCR2 CCL2 (MCP-1), CCL8 (MCP-2), CCL7
(MCP-3), CCL13 (MCP-4), CCL16
(HCC4)
Mono
(im
CCR3 CCL11 (eotaxin), CCL24 (eotaxin-2),
CCL7 (MCP-3), CCL5 (RANTES),
CCL8 (MCP-2), CCL13 (MCP-4)
Eosin
Th
CCR4 CCL17 (TARC), CCL22 (MDC) T cell
bas
CCR5 CCL3 (MIP-1), CCL4 (MIP-1), CCL5
(RANTES), CCL11 (eotaxin), CCL14
(HCC1), CCL16 (HCC4)
T cell
CCR6 CCL20 (MIP-3), LARC) T cell
cel
CCR7 CCL19 (ELC), CCL21(SLC) T cell
CCR8 CCL1 (I309) T cell
cel
CCR9 CCL25 (TECK) T cell
CCR10 CCL27 (CTACK), CCL28 (MEC) T cell
MIP,macrophage inflammatory protein;RANTES, regulated on activation n
monocyte chemotactic protein; HCC, hemofiltrate chemokine; Th2, type
macrophage-derived chemokine; LARC, liver and activation-regulated chem
chemokine; TECK, thymus-expressed chemokine; CTACK, cutaneous T-
globulin
From Charo and Ransohoff.19 Copyright © 2006 Massachusetts Medical Sleukocyte trafficking and influence a diverse array of normaland pathophysiologic processes, which have been exten-
sively reviewed in previous articles,1,19-22 including arterio-
genesis, angiogenesis, and skeletal muscle regeneration.
The four families of chemokines are determined by the
numbers and spacing of cysteine residues adjacent to the
amino terminus: CC, CXC, CX3C, and XC (Tables I and
II).19 Redundancy exists within the CC and CCX chemo-
kine families; multiple chemokines may activate several
receptors, whereas individual receptors may be activated by
several chemokines. In contrast, the CX3C and XC families,
so far, consist of only one chemokine receptor in each
family.20
The systematic nomenclature refers only to human
chemokines, although many human chemokines have
mouse orthologs. Mouse and human synonyms for chemo-
kine orthologs may differ, however, such as CXCL1;
growth-regulated oncogene- (GRO) for human and
keratinocyte-derived chemokine (KC) in mouse. Further-
more, human orthologs have not yet been identified for
some mouse chemokines, such as CCL6/multidrug resis-
rs
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s
Rheumatoid arthritis, multiple
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re), memory T cells
Atherosclerosis, rheumatoid
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resistance to intracellular
pathogens, type 2 diabetes
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s, basophils, mast cells,
telets
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skin
nocytes HIV-1 coreceptor (T-topic
strains), transplant rejection
egulatory and memory), B
dritic cells
Mucosal humoral immunity,
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dendritic cells to lymph node,
antigen presentation, and
cellular immunity
2), monocytes, dendritic Dendritic-cell migration to
lymph node, type 2 cellular
immunity, granuloma
formation
 plasma cells Homing to T cells and IgA
plasma cells to the intestine,
inflammatory bowel disease
T-cell homing to intestine and
skin
l T-cell expressed and secreted;HIV, human immunodeficiency virus;MCP,
lper T cell; TARC, thymus and activation-regulated chemokine; MDC,
; ELC, Epstein-Barr I1-ligand chemokine; SLC, secondary lymphoid-tissue
tracting chemokine; MEC, mammary-enriched chemokine.; IG, immuno-
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chemokines have been referred to as the human synonym,
unless otherwise specified by “mouse.”
The CC chemokines (Table I) primarily attract mono-
nuclear cells, including monocytes, eosinophils, basophils,
dendritic cells, and T lymphocytes.19 CCL2/monocyte
chemotactic protein-1 (MCP-1) is one of the most exten-
sively studied chemokines in hind limb ischemia models.1
CXC chemokines (Table II) primarily attract neutrophils
(CXCL1-3 and 5-8) or lymphocytes (CXCL4 and 9-16).21
Monocytes/macrophages are important in arteriogen-
esis,11 angiogenesis,24,25 and muscle regeneration,26,27
and multiple chemokines/chemokine receptors induce
monocyte/macrophage recruitment.19 Monocytes are cir-
culating cells that are recruited to sites of inflammation and
differentiate into macrophages when activated in tissues.20
Peripheral bloodmonocytes express CCR1, CCR2, CCR3,
CCR5, and CXCR4.28-30 CCR2 and CCR3 expression are
decreased during differentiation to macrophages, whereas
CCR1, CCR4, CCR5 and CXCR4 expression remain
high,29 possibly to keep activated macrophages at the site of
inflammation.20 CCR2 is the only known receptor for
CCL2. Of interest is that CCL2 has a nonredundant role in
regulating monocyte infiltration during inflammation,19 as
demonstrated by CCL2–/– and CCR2–/– mice that exhibit
deficient monocyte recruitment in essentially every tissue
under a broad range of inflammatory-inducing condi-
tions.31 Thus, a large array of chemokines can affect mono-
cytes/macrophage recruitment and thereby influence arte-
Table II. The CXC, CX3C, and XC families of chemokine
Receptor Chemokine ligands
CXCR1 CXCL8 (interleukin-8),
CXCL6 (GCP2)
Neutrophil
CXCR2 CXCL8, CXCL1 (GRO),
CXCL2 (GRO), CXL3
(GRO), CXCL5 (ENA-
78), CXCL6
Neutrophil
microvas
CXCR3-A CXCL9 (MIG), CXCL10
(IP-10), CXCL11 (I-
TAC)
Type 1 help
mesangia
CXCR3-B CXCL4 (PF4), CXCL9
(MIG), CXCL10 (IP-
10), CXCL11
Microvascu
neoplasti
CXCR4 CXCL12 (SDF-1) Widely exp
CXCR5 CXCL13 (BCA-1) B cells, foll
CXCR6 CXCL16 (SR-PSOX) CD8 T c
and mem
CX3CR1 CX3CL1 (fractalkine) Macrophag
smooth m
XCR1 XCL1 (lymphotactin),
XCL2
T cells, nat
GCP, Granulocyte chemotactic protein; COPD, chronic obstructive pulm
neutrophil-activating peptide; MIG, monokine induced by interferon-;
chemoattractant; PF, platelet factor; SDF, stromal-cell-derived factor; HIV
scavenger receptor for phosphatidylserine-containing oxidized lipids.
From Charo and Ransohoff.19 Copyright © 2006 Massachusetts Medical Sriogenesis and the tissue response to ischemia.CHEMOKINES AND ARTERIOGENESIS
Brief review of arteriogenesis. Arteriogenesis is defined
as the structural enlargement by growth of pre-existing arte-
riolar connections into true collateral arteries.11,32 Collateral
arteries can increase their lumen size by active proliferation
and remodeling, thus increasing the capacity to carry blood to
ischemic regions.33 Under normal circumstances, small
amounts of blood flow may occur within a pre-existing net-
work of arteriolar connections.With sudden arterial occlusion
secondary to an embolus or a slowly progressive stenosis, a
pressure gradient develops across the arteriolar network caus-
ing increased blood flow velocity with a concomitant change
in fluid shear stress. Increased fluid shear stress results in
increased production of endothelial adhesion molecules34,35
and production of CCL2.36
Inflammatory cells, especially monocytes/macrophages,
are attracted to the collateral artery by CCL2 and traverse the
vessel wall by binding to the adhesionmolecules.Monocytes/
macrophages can produce large amounts of growth factors24
and, in turn, may stimulate endothelial and smooth muscle
cell proliferation, both of which are necessary for collateral
artery growth.11 As the collateral artery grows, the disturbed
flow that creates different regions of high and low fluid shear
stress may normalize, possibly signaling to the collateral artery
to cease growing, despite the persistence ischemia in distal
tissue beds.
Chemokines important in arteriogenesis. Transcrip-
tional profiling of the nonischemic adductor muscle in the
d chemokine receptors
ll types Disease connection
nocytes Inflammatory lung disease, COPD
nocytes,
endothelial cells
Inflammatory lung disease,
COPD, angiogenic for tumor
growth
lls, mast cells,
s
Inflammatory skin disease,
multiple sclerosis, transplant
rejection
dothelial cells,
s
Angiostatic for tumor growth
HIV-1 coreceptor (T-cell-tropic),
tumor metastases,
hematopoiesis
helper T cells Formation of B-cell follicles
atural killer cells,
D4 T cells
Inflammatory liver disease,
atherosclerosis (CXCL16)
dothelial cells,
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Atherosclerosis
iller cells Rheumatoid arthritis, IgA
nephropathy, tumor response
disease; GRO, growth-regulated oncogene; ENA, epithelial-cell-derived
. interferon-inducible protein 10; I-TAC, interferon-inducible T-cell 
an immunodeficiency virus; BCA-1, B-cell chemoattractant 1;SR-PSOX,
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well as CXC chemokines murinemacrophage inflammatory
protein-2 (MIP-2), CXCL9, and CXCL10.13 Although
these data are suggestive that these factors are important in
collateral artery formation, involvement in other processes
occurring simultaneously in the adductor muscle cannot be
excluded.13
The most extensively studied chemokine contribut-
ing to arteriogenesis is CCL2.32 In extensive studies of a
rabbit hind limb model, Schaper et al37 infused CCL2
into the proximal end of ligated femoral arteries. After 7
days, angiograms demonstrated an increase in collateral
artery formation in the CCL2-treated animals and hemo-
dynamic measurements revealed an increase in collateral
conductance.37 Increased monocyte accumulation in the
walls of collateral arteries in the CCL2-treated animals
compared with controls was also observed. Infusion of
intercellular adhesion molecule-1 (ICAM-1) antibody
diminished the CCL2-induced increase in collateral ar-
tery formation, suggesting the CCL2 mechanism of
action was recruitment of inflammatory cells.38 Maximal
endothelial and smooth muscle cell proliferation oc-
curred at 3 days after femoral artery ligation and corre-
sponded to monocyte adherence and migration through
the collateral artery wall.39 Monocyte accumulation was
greatest at 3 days, and CCL2 infusion augmented this
response. After 7 days, monocytes were rarely observed
in collateral arteries.40
Hind limb ischemia studies using CCL2–/– mice have
consistently documented decreased restoration of perfu-
sion.41-43 One curious finding is that results in studies of
restoration of perfusion using CCR2–/– mice, the main
receptor for CCL2,1 have been variable: one study exhib-
ited decreased restoration of perfusion in CCR2–/– mice44
and two reports demonstrated similar perfusion45,46 as
control mice. Several possibilities may explain these seem-
ingly contradictory results:
First, CCL2 may function through receptors other
than CCR2,47 and the loss of CCL2 signaling through
these undefined receptors may be responsible for the de-
layed restoration of perfusion in CCL2–/– mice.
Alternatively, CCR2–/– mice exhibit increased tissue
CCL2 compared with control mice in response to hind
limb ischemia.45 Increased CCL2 may allow binding to
alternate receptors that are not normally activated at phys-
iologic levels of CCL2 and may compensate for the loss of
CCR2 receptors.
Finally, CXCR3 is another receptor that maybe impor-
tant in arteriogenesis.41 CXCR3–/– mice demonstrated
decreased collateral artery formation and impaired restora-
tion of perfusion after femoral artery ligation. Of interest
was that the infusion of bone marrow mononuclear cells
from wild-type, but not CXCR3–/– mice, resulted in nor-
mal restoration of perfusion and collateral artery density in
CXCR3–/– mice, suggesting that bone marrow–derived
cell CXCR3 expression was essential for arteriogenesis.41CHEMOKINES AND ANGIOGENESIS
Brief review of angiogenesis: role of vascular endo-
thelial cell growth factor andmonocytes/macrophages.
Vascular endothelial growth factor (VEGF) is one of the
most important factors in angiogenesis, and hypoxia is a
potent inducer of VEGF48,49 The three VEGF receptors
are VEGFR-1 (Flt-1), VEGFR-2 (KDR or Flk-1), and
VEGFR-3 (Flt-4). VEGFR-2 mediates the angiogenic ef-
fects of VEGF after embryogenesis. The role of VEGFR-1
in angiogenesis is more controversial, but it is thought to
act as a “decoy” receptor and may negatively impact angio-
genesis by binding, and thereby decreasing, the availability
of VEGF. VEGFR-3 activation mediates the lymphangio-
genic effects of VEGF.48
Angiogenesis proceeds by a carefully orchestrated series
of events, many of which are regulated by VEGF. First,
endothelial cells become activated by inflammation or
growth factors and proliferation ensues. Proteolysis of the
basement membrane, controlled mainly by the matrix met-
alloproteinases, allows for endothelial cell migration, lu-
men formation, and anastomoses with other capillaries.49
VEGF promotes endothelial cell survival, proliferation, mi-
gration, and lumen formation.50,51
Although VEGF was originally thought to act mainly
on endothelial cells, VEGF receptors are also present on
bone marrow-derived hematopoietic stem cells and inflam-
matory cells. Thus, VEGF induces the mobilization of
endothelial progenitor cells and recruits inflammatory cells,
including monocytes/macrophages.51 Of interest is that
VEGF-mediated actions on monocytes/macrophages are
accomplished by the VEGFR-1 receptor.52 In turn, mac-
rophages can produce VEGF and assist in proteolysis of the
extracellular matrix, thereby potentially amplifying the an-
giogenesis cascade.48 VEGF has a heparin-binding domain
that allows for VEGF incorporation into the extracellular
matrix. Macrophage degradation of the extracellular matrix
can release VEGF to further augment angiogenesis.53
Although monocytes/macrophages contribute angio-
genic and angiostatic factors, the overall effect of mono-
cytes/macrophages is thought to promote angiogenesis by
three potential mechanisms24,25:
First, monocytes/macrophages secrete many angio-
genic factors such as VEGF, CXCL8 (interleukin-8), gran-
ulocyte colony stimulating factor, transforming growth
factor- and , platelet-derived growth factor, tumor ne-
crosis factor-, and prostaglandins.24,25 Many of these
factors act by promoting endothelial cell proliferation, mi-
gration, or tube formation, or a combination of these.
Communication between endothelial cells and mono-
cytes/macrophages appears to be bidirectional, because
endothelial cell–secreted factors also induce chemotaxis
and increased angiogenic activity in monocytes/macro-
phages, thus initiating a positive feedback cycle. For exam-
ple, endothelial cells produce VEGF and CCL2, and both
are chemoattractants for monocytes/macrophages.25
Monocytes/macrophages must be activated to promote
angiogenesis. Activation does not lead to enhancement of
JOURNAL OF VASCULAR SURGERY
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tively increases a subset of monocytes/macrophage activi-
ties in a stimulus-dependent manner.24
Second, macrophages digest the extracellular matrix,
making it more prone to endothelial cell penetration. En-
dothelial cells migrate from established vessels to form new
capillaries; thus, a path through the extracellular matrix
must be created. Macrophages are efficient in the phagocy-
tosis of extracellular matrix to create tunnels for endothelial
cell migration. Macrophages are rich sources of matrix
metalloproteinases, the proteolytic enzymes that are essen-
tial for extracellular matrix breakdown.25 Of interest is that
CCL2-directed macrophage chemotaxis further amplifies
this tunnel-drilling process.54,55
Third, monocytes/macrophages may provide cellular
components of the vessel wall by transdifferentia-
tion.25,55,56 Monocytes/macrophages exhibit a pheno-
typic overlap of cell surface markers with sinusoidal and
microvascular endothelial cells. Under angiogenic growth
conditions, monocytes/macrophage precursors can differ-
entiate into endothelial-like cells.57,58 In vitro, peritoneal
macrophages formed tunnels in matrigel and three-dimen-
sional structures resembling microvessels.55 Thus, factors
that affect monocytes/macrophage recruitment, such as
chemokines, can influence angiogenesis.
Angiogenic and angiostatic properties of CXC che-
mokines. The CXC chemokine family members exhibit
both angiogenic properties, mediated by CXCR1, CXCR2,
and CXCR4, and angiostatic properties, mediated by
Table III. Angiogenic and angiostatic chemokines and
chemokine receptors
Receptor Chemokine Ligands
Angiogenic
CCR1 CCL15 (leukotactin-1)
CCR2 CCL2 (MCP-1)
CCR3 CCL11 (eotaxin); CCL15
CCR8 CCL1 (I309)
CXCR1 CXCL8 (interleukin-8); CXCL6
(GCP2)
CXCR2 CXCL8; CXCL1 (GRO), CXCL2
(GRO), CXL3 (GRO), CXCL5
(ENA-78), CXCL6, CXCL7
(NAP-2)
CXCR4 CXCL12 (SDF-1)
CX3CR1 CX3CL1 (fractalkine)
Angiostatic
CXCR3 CXCL4 (PF4), CXCL9 (MIG),
CXCL10 (IP-10), CXCL11 (I-
TAC)
CXCR5 CXCL13 (BCA-1)
MCP, Monocyte chemotactic protein; GCP, granulocyte chemotactic pro-
tein; GRO, growth-regulated oncogene; ENA, epithelial-cell-derived neu-
trophil-activating peptide; NAP, neutrophil-activating peptide; SDF, stro-
mal-cell-derived factor; PF, platelet factor; MIG, monokine induced by
interferon-; IP-10, interferon-inducible protein 10; I-TAC, interferon-
inducible T-cell  chemoattractant; BCA-1, B-cell chemoattractant 1.
Table derived from Bernardini et al,59 Rosenkilde and Schwartz,60 and
Hwang et al.1CXCR3 and CXCR5 (Table III).59-61 Although chemo-kines can exert a proangiogenic effect by recruitment of
inflammatory cells, CXCL1, CXCL2, CXCL3, CXCL5,
CXCL6, and CXCL8 can mediate angiogenesis in the
absence of preceding inflammation through activation of
CXCR2.62 Angiostatic chemokines are generally thought
to inhibit the actions of proangiogenic growth factors, such
as VEGF, on endothelial cell proliferation, chemotaxis, and
other processes.59 Conflicting data of proangiogenic vs
angiostatic properties of individual chemokines are com-
mon, however.
Angiogenesis is typically studied in animal models by
using a variety of in vitro endothelial cell assays. Endothelial
cells isolated from various sources express different chemo-
kine receptors and may, in part, reconcile conflicting re-
ports present in this area. In addition, limited antibodies are
available that are specific for each chemokine and chemo-
kine receptor, making difficult the determination of specific
chemokine/chemokine receptor pair effects on the differ-
ent aspects of angiogenesis.59 For example, although che-
mokines that activate CXCR3 inhibit in vitro endothelial
cell proliferation and chemotaxis (ie, angiostatic),59 de-
creased capillary density was observed in ischemic calf mus-
cles of CXCR3–/– mice after femoral artery ligation, sug-
gesting impairments in angiogenesis in the absence of
CXCR3.41
Angiogenic properties of CXCL12/stromal-cell-de-
rived factor-1 (SDF-1) may be mediated by several mech-
anisms. CXCR4, the receptor for CXCL12, is widely ex-
pressed on many cell types, including inflammatory and
endothelial cells. CXCL12 induces endothelial cell prolif-
eration, chemotaxis, and tube formation. Furthermore,
CXCL12 increases VEGF production, whereas VEGF can
upregulate CXCR4 expression on endothelial cells; thus,
VEGF and CXCL12 may act in a synergistic fashion to
promote angiogenesis.60 In addition, CXCL12 is a potent
chemotactic agent for endothelial progenitor cells that
promote angiogenesis by incorporation into capillary net-
works or by paracrine effects from endothelial progenitor
cell–secreted factors, or both.63-65
Angiogenic properties of CC chemokines. Perhaps
the most studied CC chemokine (Table III) in angiogene-
sis is CCL2. In addition to monocyte/macrophage recruit-
ment, vascular cells are also influenced by the CCL2/
CCR2 axis. Endothelial cells express CCR2, which is up-
regulated by inflammatory cytokines. CCL2 induces
endothelial cell migration, and production of CCL2 was
increased after endothelial cell injury. After mechanical
injury to endothelial cell monolayers, wound repair was
delayed by inhibition of CCL2 and was improved by addi-
tion of exogenous CCL2.66 Furthermore, CCL2 directly
induces vascular smooth muscle cell proliferation67 and
migration,68 whereas CCR2 is expressed on vascular
smooth muscle cells.69
Several studies have suggested a direct effect of CCL2
on angiogenesis in the absence of inflammation. Using the
ex vivo rat thoracic aortic ring assay, the addition of CCL2
to the media resulted in increased angiogenesis.70-72 The
CCL2-induced angiogenesis was mediated by up-regula-
JOURNAL OF VASCULAR SURGERY
Volume 45, Number A Shireman 53Ation of hypoxia-inducible factor-1, which in turn induced
VEGF-A expression. VEGF-A–activated RhoA small G
protein increased endothelial cell migration and prolifera-
tion. Inhibition of RhoA small G protein abrogated the
CCL2-induced angiogenesis without affecting the in-
creased VEGF production. This suggested that CCL2-
induced angiogenesis was composed of two sequential
steps: induction of VEGF-A expression by CCL2 with
subsequent VEGF-A–induced angiogenesis.70
Although CCL2 can induce VEGF production, VEGF
can also induce CCL2 production by the activated pro-
tein-1 binding site of the CCL2 promoter region. VEGF-
induced tubule formation in angiogenesis and vascular
permeability in the Miles assay was inhibited by anti-CCL2
antibody.73 Endothelial cells exposed to VEGF74 or brief
ischemia75 produced CCL2. Thus, endothelial cells secrete
CCL2 and VEGF, both of which are chemotactic for
monocytes/macrophages. Monocytes/macrophages also
secrete CCL2 and VEGF, which in turn, affect endothelial
cell functions, further amplifying the angiogenesis cas-
cade.48
CCL2 has also induced angiogenesis in a variety of in
vivo models. CCL2 increased angiogenesis in both the
matrigel plug and chick chorioallantoic membrane assays.71
CCL2 and VEGF induced similar increases in angiogenesis
in the rabbit cornea assay. CCL2 angiogenesis was associ-
ated with macrophage recruitment, however, which was
absent with VEGF. Of interest was that CCL2 induced a
more rapid angiogenic response than VEGF with later
vessel regression.76
In vivo measurements of capillary density in CCL2–/–
mice have been contradictory, depending on the model.
CCL2–/– mice exhibited decreased capillary density com-
pared with wild-type mice in dermal wounds77 and in
ischemic muscle after femoral artery ligation.41 In contrast,
CCL2–/– mice exhibited similar capillary density compared
with wild-type mice in a myocardial ischemia model.78
Decreased capillary density was observed in CCR2–/– mice
in association with decreased monocyte/macrophage re-
cruitment and delayed restoration of tissue VEGF after
toxic muscle injury (unpublished observation, PK Shire-
man, San Antonio, Tex, 2006).
Additional CC chemokines also exhibit proangiogenic
effects (Table III). CCL1/I309,79 CCL11/eotaxin,80 and
CCL15/leukotactin-1,61 all directly induce endothelial
cell migration as well as stimulate in vivo angiogenesis.
Finally, CC chemokine receptors CCR2 and CCR5 were
expressed on endothelial progenitor cells and may be criti-
cal for endothelial progenitor cell homing to regions of
active angiogenesis.81
Angiogenic properties of the CXC3 chemokine fam-
ily. CX3CL1/fractalkine, the only chemokine in the CXC3
family, induced endothelial cell proliferation, migration,
and tube formation as well as promoted angiogenesis in
vivo.82,83 The receptor for CX3CL1, CX3CR1, was also
expressed on endothelial cells.82
Finally, a novel, three-dimensional in vitro model of
angiogenesis used oligonucleotide arrays to evaluate geneexpression in endothelial cells during three phases of angio-
genesis: sprouting, branching, and network formation.
Multiple chemokines and chemokine receptors were ex-
pressed differentially during the various phases of angio-
genesis. Interestingly, CCL2, CCL5/regulated on activa-
tion normal T-cell expressed and secreted (RANTES) and
CX3CL1 were maximally increased during the sprouting
phase.84 This report highlights the delicate balance of
chemokines necessary for normal angiogenesis.
CHEMOKINES AND SKELETAL MUSCLE
REGENERATION
Brief review of skeletal muscle regeneration. The
three central components in skeletal muscle regeneration
are perfusion, inflammation, and satellite cells/myogenic
progenitor cells. First, perfusion is essential to muscle re-
generation. Regeneration was dependent on the invasion of
blood vessels into the transplanted muscle before regener-
ation occurred.85 In vivo, muscle regeneration occurred
from the outside of the muscle bundle toward the inner
regions,86 possibly secondary to the need for capillaries to
form before muscle regeneration could proceed. Thus,
angiogenesis was critical to muscle regeneration, and im-
pairments in angiogenesis could lead to altered muscle
regeneration.
Second, inflammatory cells infiltrate the area after mus-
cle damage, and neutrophils predominate initially. Neutro-
phils are key players in early inflammation associated with
muscle injury, but these cells can also exaggerate muscle
damage.26,87 Although some reports claim a beneficial or
neutral role of neutrophils in muscle regeneration,88,89
most suggest that neutrophils increase muscle injury by
generation of oxidant stress.26,87,90 In fact, myeloperoxi-
dase may be a major factor in neutrophil-mediated damage;
for example, myeloperoxidase–/– mice had less muscle
membrane injury induced bymechanical loading than wild-
type mice despite similar levels of inflammation.90
Neutrophils also secrete substances that attract and
activate macrophages.91 This is important because macro-
phages replace neutrophils to facilitate the resolution of
inflammation.92 Thus, the initial neutrophil inflammatory
infiltrate was replaced by macrophages. Within 3 days after
injury, macrophages predominated during skeletal muscle
regeneration and were essential for the removal of necrotic
tissue. Macrophages also produce a vast array of growth
factors and enzymes that influence many aspects of the
regenerative process, including angiogenesis and the che-
motaxis, proliferation, and differentiation of myoblasts.93
Third, satellite cell activation is required to repair or
replace the injured muscle. Satellite cells are a small popu-
lation of resident muscle progenitor cells that are multipo-
tent. Satellite cells are quiescent in normal muscle, but
become activated and proliferate in response to muscle
damage and express myogenic markers (now termed myo-
blasts). Myoblasts ultimately fuse to existing muscle or fuse
together to form new myofibers during regeneration of
damaged skeletal muscle tissue.6 Satellite cells may arise
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June Supplement 200754A Shiremanfrom several different sources and controversy exists about
their origin.6
Importance chemokines in muscle regeneration.
Transcriptional profiling of injured skeletal muscle under-
going regeneration demonstrated increases in a variety of
chemokines and chemokine receptors, especially in the CC
family: CCL2, CCL3, CCL4, CCL6, CCL7, CCL9, and
CCL12 as well as the CXC chemokine MIP-2 (mouse)
were elevated after toxin-induced94,95 and freeze-in-
duced96 muscle injury. Chemokine receptors CXCR4,
CCR1, CCR2, and CCR5 were also elevated.95 Similar
results were obtained from ischemic posterior calf muscles
after femoral artery ligation.97 Of note, the histologic ap-
pearance of regenerating muscle was similar after toxic,
freeze, and ischemic injury,95-98 suggesting that the muscle
regeneration process was similar regardless of the inciting
injury.
Skeletal muscle is able to regenerate after injury because
of myogenic progenitor cells that are able to proliferate and
repair/replace damaged muscle.6 Proliferating myoblasts
secrete the neutrophil chemoattractant factor CXCL5/
LPS-inducible CXC chemokine (LIX, mouse)99 as well as
macrophage chemotactic factors CCL2 and CX3CL1.
100
The presence of macrophages enhanced myoblast prolifer-
ation while reducing myoblast apoptosis, potentially facili-
tating muscle regeneration.100 Myoblasts also express che-
mokine receptors CCR2101 and CXCR4,102 suggesting
that myoblast chemotaxis into injured tissue may be di-
rected by chemokines. Thus, myoblasts are able to secrete
and respond to chemokines.
In necrotic muscle after femoral artery excision, muscle
regeneration was impaired in CCL2–/– mice43 and
CCR2–/– mice45 in association with decreased macrophage
recruitment. Because differences in arteriogenesis could
potentially lead to a more prolonged and severe ischemic
insult, thereby impairing skeletal muscle regeneration,
toxic muscle injury was also performed and exhibited sim-
ilar impairments in muscle regeneration and macrophage
recruitment (unpublished observation, PK Shireman, San
Antonio, Tex, 2006). Impaired muscle regeneration in
CCR2–/– mice was also observed after freeze injury,103
whereas CCR5–/– mice exhibited normal muscle regener-
ation.104 Of interest was that partial macrophage depletion
also resulted in similar impairments in muscle regenera-
tion,105 suggesting that macrophage recruitment by the
CCL2/CCR2 axis may be crucial to normal muscle regen-
eration.
CONCLUSIONS
Arteriogenesis, angiogenesis, and muscle regeneration
are complex, interrelated processes that involve multiple
cell types. Chemokines by direct and inflammatory-medi-
ated mechanisms play an integral role in all three of these
processes. A better understanding of the cellular interac-
tions necessary for the successful formation of collateral
arteries and recovery of injured tissues may lead to more
successful strategies for tissue regeneration and engineer-
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